Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9914447rdf:typepubmed:Citationlld:pubmed
pubmed-article:9914447lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C0917798lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C0021308lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C0521654lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C0449468lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C0665690lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C1414601lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C0205234lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:9914447lifeskim:mentionsumls-concept:C1550147lld:lifeskim
pubmed-article:9914447pubmed:issue1lld:pubmed
pubmed-article:9914447pubmed:dateCreated1999-3-12lld:pubmed
pubmed-article:9914447pubmed:abstractTextFibroblast growth factor-13 (FGF-13), novel member of FGF family has recently been molecularly cloned as a result of high throughput sequencing of a ovarian cancer cell, hippocampal, and kidney cDNA libraries. The human gene encodes for a protein with a molecular weight of 22 kDa that is most homologous to FGF-8 (70% similarity). In the current study, we tested the effects of intravenously administered FGF-13 in a model of permanent focal cerebral ischemia in Sprague-Dawley rats. FGF-13 or the vehicle was administered systematically via the tail vein 30 min prior, and 30 min and 24 h after the occlusion of the left middle cerebral artery (MCAo). Animals were weighed and evaluated behaviorally prior to and at 24 and 48 h after MCAo. The volume of cerebral infarct and swelling were determined using an image analysis system (BioQuant) and cresyl violet stained sequential sections from the forebrain region. Histopathology was evaluated to compare the therapeutic effects. We found a 63% reduction in infarct volume in FGF-13- vs. vehicle-treated animals (infarct volume was 21.9+/-3.8% in vehicle- and 8.1+/-1.6% in FGF-13-treated rats, p=0.0016) and a moderate inhibition of brain swelling by FGF-13. The reduction in infarct volume and brain swelling were associated with improvement of clinical deficits in FGF-13 treated animals (p<0.001). Histopathological examination determined that nervous tissue was better preserved in FGF-13 treated rats than those of controls. These data show that pretreatment with intravenous FGF-13 reduces infarct size and ameliorates neurological deficits following permanent focal cerebral ischemia in rats.lld:pubmed
pubmed-article:9914447pubmed:languageenglld:pubmed
pubmed-article:9914447pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9914447pubmed:citationSubsetIMlld:pubmed
pubmed-article:9914447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9914447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9914447pubmed:statusMEDLINElld:pubmed
pubmed-article:9914447pubmed:monthFeblld:pubmed
pubmed-article:9914447pubmed:issn0006-8993lld:pubmed
pubmed-article:9914447pubmed:authorpubmed-author:LincolnCClld:pubmed
pubmed-article:9914447pubmed:authorpubmed-author:LiL YLYlld:pubmed
pubmed-article:9914447pubmed:authorpubmed-author:AldersonR FRFlld:pubmed
pubmed-article:9914447pubmed:authorpubmed-author:AntonaccioMMlld:pubmed
pubmed-article:9914447pubmed:authorpubmed-author:YaoD LDLlld:pubmed
pubmed-article:9914447pubmed:authorpubmed-author:MasonicKKlld:pubmed
pubmed-article:9914447pubmed:authorpubmed-author:PetulloDDlld:pubmed
pubmed-article:9914447pubmed:authorpubmed-author:WibberleyLLlld:pubmed
pubmed-article:9914447pubmed:copyrightInfoCopyright 1999 Elsevier Science B.V.lld:pubmed
pubmed-article:9914447pubmed:issnTypePrintlld:pubmed
pubmed-article:9914447pubmed:day6lld:pubmed
pubmed-article:9914447pubmed:volume818lld:pubmed
pubmed-article:9914447pubmed:ownerNLMlld:pubmed
pubmed-article:9914447pubmed:authorsCompleteYlld:pubmed
pubmed-article:9914447pubmed:pagination140-6lld:pubmed
pubmed-article:9914447pubmed:dateRevised2003-12-15lld:pubmed
pubmed-article:9914447pubmed:meshHeadingpubmed-meshheading:9914447-...lld:pubmed
pubmed-article:9914447pubmed:meshHeadingpubmed-meshheading:9914447-...lld:pubmed
pubmed-article:9914447pubmed:meshHeadingpubmed-meshheading:9914447-...lld:pubmed
pubmed-article:9914447pubmed:meshHeadingpubmed-meshheading:9914447-...lld:pubmed
pubmed-article:9914447pubmed:meshHeadingpubmed-meshheading:9914447-...lld:pubmed
pubmed-article:9914447pubmed:meshHeadingpubmed-meshheading:9914447-...lld:pubmed
pubmed-article:9914447pubmed:meshHeadingpubmed-meshheading:9914447-...lld:pubmed
pubmed-article:9914447pubmed:meshHeadingpubmed-meshheading:9914447-...lld:pubmed
pubmed-article:9914447pubmed:meshHeadingpubmed-meshheading:9914447-...lld:pubmed
pubmed-article:9914447pubmed:year1999lld:pubmed
pubmed-article:9914447pubmed:articleTitlePretreatment with intravenous FGF-13 reduces infarct volume and ameliorates neurological deficits following focal cerebral ischemia in rats.lld:pubmed
pubmed-article:9914447pubmed:affiliationDepartment of Pharmacology, Human Genome Sciences, 9410 Key West Avenue, Rockville, MD 20850, USA.lld:pubmed
pubmed-article:9914447pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:2258entrezgene:pubmedpubmed-article:9914447lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9914447lld:pubmed